Anavex Life Sciences
AVXL
65 hedge funds and large institutions have $32.6M invested in Anavex Life Sciences in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
5% more funds holding
Funds holding: 62 → 65 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.87% less ownership
Funds ownership: 23.8% → 22.93% (-0.87%)
21% less capital invested
Capital invested by funds: $41.5M → $32.6M (-$8.91M)
55% less call options, than puts
Call options by funds: $394K | Put options by funds: $869K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$305K |
| 2 |
Bank of New York Mellon
New York
|
+$263K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$196K |
| 4 |
Morgan Stanley
New York
|
+$162K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$110K |
Top Sellers
AVXL Hedge Fund Activity: Q4 2017 in Review
65 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q4 2017, worth a combined $32.6M — down 21% from $41.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AVXL positions and 7 closed out — a net gain of 3 holders — while 21 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $305K. The largest seller was Park West Asset Management, cutting an estimated $632K.
- 65 institutional investors held Anavex Life Sciences (AVXL) as of Q4 2017, up from 62 in Q3 2017.
- Funds reported $32.6M of Anavex Life Sciences stock for Q4 2017, down 21% quarter-over-quarter.
- 10 funds opened new Anavex Life Sciences positions in Q4 2017 and 7 closed out, a net change of +3 holders.
- The largest Anavex Life Sciences buyer in Q4 2017 was Vanguard Group, an estimated $305K added.
- The largest Anavex Life Sciences seller in Q4 2017 was Park West Asset Management, an estimated $632K sold.
Based on aggregated 13F filings for Q4 2017.